CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Amicus Therapeutics

Patrik Florencio, SVP and Chief Compliance & Risk Officer

How Technology Enhances The Effectiveness Of Compliance Programs

Patrik Florencio

Patrik Florencio

For global life science companies, the challenge of maintaining effective oversight and control over dozens of activities taking place simultaneously across multiple jurisdictions can be daunting—especially when such companies rely on paper processes. As anyone who has been audited or investigated knows painfully well, if you can’t prove oversight and control through documentation, then such oversight and control didn’t happen. This underscores the vital importance of documentation and the weakness of paper processes. When it comes time for non-automated compliance programs to demonstrate effectiveness, documentation is often missing because compliance officers across multiple jurisdictions are saving their documentation onto different computer systems or servers, forgetting to scan and upload required documentation, and/or are unable to demonstrate version control. This is where technology can save the day.


At Amicus, we use a single, global, compliance approval system to review and approve activities taking place around the world. So, regardless of whether the activity involves the French business team hiring a physician in France, the Japanese business team conducting an advisory board in Japan, or the US business team sponsoring medical education in the US, all requests for approval are submitted using the exact same online compliance approval system, which we’ve called the Amicus Compliance Engine (ACE). ACE is powered by an out-of-the-box, yet highly configurable, compliance automation software provided by Lextegrity, a leading software firm started by former in-house life sciences compliance and audit professionals. When new submissions are entered into ACE by the business, Amicus compliance officers receive immediate email notifications and can log-on at any time to review those submissions. But the great advantage of this system is that it serves as a single point of control and documentation for the vast majority of global activities requiring compliance approval. Regardless of geographic location, the business must upload into ACE all information regarding the activity and complete the relevant ACE approval form, which means all information related to the submission gets documented in ACE. Likewise, all information related to approval also gets documented in ACE, including compliance officer activities like follow-up questions to submitters, due diligence, and final approval.


But compliance approval systems with an open architecture that are highly customizable are even more valuable. 


In pharmaceuticals, the corporate compliance function typically oversees the activities of the commercial, medical, patient advocacy, and clinical departments. As such, many compliance approval systems focus on controls related to those departments. However, compliance departments are evolving and at many companies are tasked with responsibilities that extend beyond the traditional areas of oversight. For example, a compliance department may be responsible for managing employee-reported conflicts of interest, for conducting due diligence on third parties, for reviewing patient-related activities, and/or for driving the company’s privacy program, including the review of privacy impact assessments under the GDPR. So, the more a compliance approval system can be customized to cover all areas, both traditional and non-traditional, the more valuable it will be as a single point of control and documentation.


Compliance approval systems with an open architecture that are highly customizable are even more valuable


Yet most valuable of all are compliance approval systems that also allow for real-time integration and key data transfer to other systems. For example, at Amicus, ACE is connected to our contract management system. So, once data related to an activity is entered by the business into ACE, the business doesn’t need to re-enter that same information into the contract management system in order to get a contract. Rather, after the activity has been approved in ACE, the data related to that activity is automatically transferred to the contract management system, and out pops a contract, leading to a happy business partner. Not only is this process efficient and user-friendly for the business, but it also serves as an additional compliance control, because the only way for the business to get a contract is to submit the activity in ACE and have it approved by the compliance department.


In sum, technology-based compliance approval systems offer not only a single point of global control and documentation, which is key from a compliance program perspective, but also permit an efficient and user-friendly experience for the business. A true win-win for all.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://therapeutics.lifesciencesreview.com/leadership-perspective/how-technology-enhances-the-effectiveness-of-compliance-programs-nwid-295.html